ESMO: Regeneron Mounts Credible Challenge To Keytruda With Libtayo Survival Data In NSCLC
Claims ‘Best-In-Class’ Status
Libtayo looks to have surpassed all competitors but Merck’s Keytruda in first line NSCLC, but the unique ‘all-comers’ trial design of EMPOWER-Lung-3 complicates the picture.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.